Pneumocandins from Zalerion arboricola. IV. Biological evaluation of natural and semisynthetic pneumocandins for activity against Pneumocystis carinii and Candida species
- PMID: 1490879
- DOI: 10.7164/antibiotics.45.1886
Pneumocandins from Zalerion arboricola. IV. Biological evaluation of natural and semisynthetic pneumocandins for activity against Pneumocystis carinii and Candida species
Abstract
A series of lipopeptide compounds co-produced during the fermentation of pneumocandin A0 (L-671,329) and related semisynthetic compounds were evaluated in vivo against Pneumocystis carinii pneumonia and systemic candidiasis. In addition, they were tested in vitro against a panel of pathogenic Candida species and in a Candida membrane 1,3-beta-D-glucan synthesis assay. The results of these studies demonstrate that pneumocandin A0 and pneumocandin B0 (L-688,786) are the most potent compounds when considering both antipneumocystis and anticandida activity. Other compounds in the series are selectively more potent against P. carinii or Candida albicans suggesting a diverging structure-activity relationship. Evaluation of these compounds for their ability to inhibit C. albicans 1,3-beta-D-glucan synthesis in vitro demonstrates that they inhibit this process. A positive correlation between 1,3-beta-D-glucan synthesis inhibition and in vitro antifungal activity was also demonstrated for some of the pneumocandins.
Similar articles
-
Pneumocandins from Zalerion arboricola. I. Discovery and isolation.J Antibiot (Tokyo). 1992 Dec;45(12):1853-66. doi: 10.7164/antibiotics.45.1853. J Antibiot (Tokyo). 1992. PMID: 1490876
-
Pneumocandins from Zalerion arboricola. III. Structure elucidation.J Antibiot (Tokyo). 1992 Dec;45(12):1875-85. doi: 10.7164/antibiotics.45.1875. J Antibiot (Tokyo). 1992. PMID: 1490878
-
Pneumocandins from Zalerion arboricola. II. Modification of product spectrum by mutation and medium manipulation.J Antibiot (Tokyo). 1992 Dec;45(12):1867-74. doi: 10.7164/antibiotics.45.1867. J Antibiot (Tokyo). 1992. PMID: 1490877
-
Design and preparation of cyclopeptamine antifungal agents.Curr Pharm Des. 1999 Feb;5(2):57-71. Curr Pharm Des. 1999. PMID: 10066884 Review.
-
Biosynthesis of pneumocandin lipopeptides and perspectives for its production and related echinocandins.Appl Microbiol Biotechnol. 2018 Dec;102(23):9881-9891. doi: 10.1007/s00253-018-9382-x. Epub 2018 Sep 25. Appl Microbiol Biotechnol. 2018. PMID: 30255232 Review.
Cited by
-
Structural Diversity and Biological Activities of Fungal Cyclic Peptides, Excluding Cyclodipeptides.Molecules. 2017 Nov 27;22(12):2069. doi: 10.3390/molecules22122069. Molecules. 2017. PMID: 29186926 Free PMC article. Review.
-
Natural products: a continuing source of novel drug leads.Biochim Biophys Acta. 2013 Jun;1830(6):3670-95. doi: 10.1016/j.bbagen.2013.02.008. Epub 2013 Feb 18. Biochim Biophys Acta. 2013. PMID: 23428572 Free PMC article. Review.
-
Semisynthetic echinocandins affect cell wall deposition of Pneumocystis carinii in vitro and in vivo.Antimicrob Agents Chemother. 1996 Aug;40(8):1811-6. doi: 10.1128/AAC.40.8.1811. Antimicrob Agents Chemother. 1996. PMID: 8843286 Free PMC article.
-
Evaluation of the echinocandin antifungal MK-0991 (L-743,872): efficacies in mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis.Antimicrob Agents Chemother. 1997 Nov;41(11):2333-8. doi: 10.1128/AAC.41.11.2333. Antimicrob Agents Chemother. 1997. PMID: 9371329 Free PMC article.
-
Novel enzyme-linked immunoassay to determine nanogram levels of pneumocandins in human plasma.J Clin Microbiol. 1998 May;36(5):1414-8. doi: 10.1128/JCM.36.5.1414-1418.1998. J Clin Microbiol. 1998. PMID: 9574717 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
